Myocarditis following mRNA vaccination against SARS-CoV-2, a case series

Introduction: mRNA COVID-19 vaccines have emerged as a new form of vaccination that has proven to be highly safe and effective against COVID-19 vaccination. Rare adverse events including myocarditis have been reported in the literature. Methods: Data were gathered from the electronic medical record of four patients personally treated by the authors. Results: Four patients, ages 20 to 30, presented with myocarditis characterized by chest pain, elevations in troponin-I and C-reactive protein, and negative viral serologies two to four days following mRNA vaccine administration. One had a cardiac MRI showing delayed gadolinium enhancement in a subpericardial pattern. All experienced symptom resolution by the following day, and the two who have returned for follow-up had normal troponin-I and CRP values. Discussion: Along with previously reported instances, these cases raise suspicion for a possible link between mRNA vaccines and myocarditis.